7 07 June 2021 Semaglutide 2.4 mg approval in the US Wegovy TM ready for launch o Less than 3% of PwO in the US are treated with AOMs Million 100 106 80 60 40 ~30% 20 <3% 0 PwO Seeks help Treated with AOMs Continued reco new-to NBRx count (000s) Mid-Mar 6 5 4 3 2 1 0 Jan 2 2 0 J0 2 a2 0 n0 Saxend Lockdow AOM: Anti-obesity medication; HCP: Healthcare professionals; PwO: People with obesity Note: Percentages are of the 106 m Services. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017 – 2018 Craig M. Hales, M.D., Marga Ogden, Ph.D.; seeks help: Pharmetrics-aEMR linked database; Treated with AOMs: IQVIA AOM LAAD FY2020; NBRx graph:
Download PDF file